For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for subsequent MRD measurements ...

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA approval for AUCATZYL®, a ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

An acute myeloid leukemia (AML) rash may appear in the form of small spots or bruises. On light skin, AML rash often appears as red or purple spots. On dark skin, it may look darker and be less ...

Acute lymphocytic leukemia (ALL) typically responds well to traditional chemotherapy. If ALL has certain features, targeted therapies, immunotherapy, and stem cell transplants may be considered.

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia ... Radon, Even at Levels Below EPA Guideline for Mitigation, Is Linked to Childhood Leukemia ...

Chronic myelomonocytic leukemia (CMML) is a rare type of blood cancer. Some people live a long time with CMML, but others go on to develop acute myeloid leukemia (AML). Chronic myelomonocytic ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Acute lymphoblastic leukemia/lymphoma (ALL), also called acute lymphocytic leukemia and acute lymphoid leukemia, is a type of blood cancer that starts with a change to a single cell in the bone marrow ...